Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks, Foo, for that and your subsequent post on the matter.
Fiscal year ended on September 30th. I believe Anavex has 75 days to file its 10-K, which is December 14th.
Does anyone know if TGD is attending, virtual or otherwise?
Jefferies London Healthcare Conference
NOVEMBER 14-16 • LONDON, UK
IMO, no Rett data until after the 10-K is filed, hence after the fiscal year end cc. My thinking if they disclose Rett before then, Anavex will need to include a summary of it in the 10-K, which brings the SEC into the picture. Lawyers and accountants would prefer to wait on these big events until after periodic filings are made and state data is being analyzed. Then, release the data a week later.
That's easy ... unless you don't understand the word "tomorrow" on a Tuesday means "Wednesday!"
But it did not hit $5.75 on Wednesday ... as you stated it would.
No, you stated:
It didn't and you were wrong ... just admit it.
It did not hit $5.75 today, Ziggy!
DFRAI, it doesn't.
So, what are your thoughts, Investor?
If you recall, the shorts' attorneys did file a case in 2015-6 with a plaintiff who owned 100 shares. The lawsuit was thrown out because it was ... 💩💩💩!!!
Musing during a MoW route today:
1) If the Rett Excellence trial results are just that "Excellent," that BP's eyes are opened wider to the potential of small molecules and the validity of homeostasis, such that a low rumble will begin for one of them to buy-out Anavex, which would not maximize shareholder value in the long run? [BP is anxious to read the Rett numbers, too, as many are interested in small molecules and homeostasis.]
2) To minimize that threat, would Anavex then time the Rett release to a period slightly before the peer review paper on the Alzheimer's P2b/3 trail results, thus establishing a higher value for Anavex?
3) TGD has a problem if Alzheimer's peer review release goes into 2024, given his committed to release Rett this year.
IMO, the two are released within a week of each other in 2023 or Rett will be released mid-December if peer review is not forthcoming in 2023.
Agree.
Investor, add another $10/share to his losses. Poor man … he’s down $39 million, + or - a few.
Investor, I calculate he paid roughly $297 for BIIB and yesterday's price was $245.61. I get a loss > $50/share ... and it is down early today ... now up.
Good to know, X. Prayers will continue for you from me and biostockclub.
God bless you, X, and your family.
By Cecile Mantovani and Gabrielle Tétrault-Farber
November 6, 202311:52 AM CST Updated 17 hours ago
https://www.reuters.com/business/healthcare-pharmaceuticals/swiss-designed-technology-helps-parkinsons-patient-walk-again-2023-11-06/
X, nice to hear from you. I went to Notre Dame Grotto and had a prayer from two years ago that biostockclub sent me for you and your cancer battle. I'm sure he, wherever he is, would like to know how you are doing, as well as the rest of us.
Best health to you, X.
vispach, my guess it was mistyped and s/b 2023, not 2022.
mrp, Anavex is working to restore damaged cells via homeostatis. Article was posted to show what other folks are doing. This outfit is taking a different tactic in a P1; long way to go and possibly futility for it.
I like our homeostasis approach.
Apparently, Rikker figured out that one may leave two emoji's for each post.
abe, don't worry about me. It's the mrp's, ath's, and raja's about whom we need to be concerned. Previous supporters, now, not so much. Hopefully, they see the light before it is TOO BRIGHT.
2nd Half of 2023 ... still 58 days until 1/1/2024. Please no BS about when people take holidays, etc. It only takes "ONE" day to release a PR ... including multiple PR's. 🤞
william, I think it is mrp, just back from China, with lots of investors $$ in his pocket to buy AVXL.
Welcome back, mrp. Do you need to quarantine yourself? 😉
Foo, what do you make of it? I'm confused with its statement that the data is "blinded," so how do they know what it is?
TIA for your reply.
So, Baked, what did BIVI present last week @ CTAD? Based on the interview posted yesterday, the CEO stated it was presenting @CTAD in Boston (I assume interview took place prior to that conference). Did you hear any news from CTAD? Any buzz and/or trite-ups?
Reyeton, the reason why Anavex is 20th is due to MC ... Anavex has the lowest MC of the 20. No indication of potential, unfortunately.
We complain about shorts ... per Fidelity, SAVA has 14 M shares short or 35+% of o/s shares.
No problem, attila.
You enjoy yours as well. It would be appropriate to have the Rett data come out this month as it is Rett Awareness Month.
P.S. I noticed he did not "man-up" ... but, why am I not surprised.
attila, I told him he had it wrong; that is why I had it in quotes. He changed it within the 15 minutes.
Maybe, he'll man-up and admit it.
So, PR pros here, if you were writing a PR for two future events, do you list first the one that will happen sooner or the one with more impact, but will occur second?
TIA
Missing, Anavex is going after AA with bio markers that exceed the results of the-mass that have received AA. As to the confirmatory trial, that proof may available now if Anavex did a 48-week evaluation (as Investor suggested months back) on the former placebo participants; everyone in the 96-week OLE has surpassed the 48 week time period.
As to a Far East partner, Takeda would be a bigger, better and more trusted (Consortium member with Anavex) partner. Why have anything to do with your enemy that wants you to turn to dust?
mrp, that might explain the additional time Anavex is taking in the Alzheimer's P2b/3 trial's NDA. It may be working to show the relationship and respective benefits 2-73 has with other diseases, besides AD. With which, S1R tie in will lead to 3-71's quicker approval.